Mizumatsu Shinichiro, Nomura Ryutaro
Cyberknife Center, Aoyama General Hospital, Toyokawa, JPN.
ZAP Center, Kamiyacho Neurosurgical Clinic, Tokyo, JPN.
Cureus. 2023 Dec 28;15(12):e51227. doi: 10.7759/cureus.51227. eCollection 2023 Dec.
Diffuse large B-cell lymphoma (DLBCL) of the skull is rare, and there are no reports of treatment using CyberKnife (CK). Here, we report the case of a patient with skull DLBCL treated with low-dose CK radiotherapy (CKR), resulting in effective local control. The patient was a 75-year-old man who was initially diagnosed with multiple skull metastases (frontal, occipital, right orbital bones) from renal pelvic cancer. We initially created a CKR treatment plan for the frontal bone lesion with a marginal dose of 35 Gy and a maximum of 64.8 Gy in five fractions every other day. Because the frontal bone lesion shrank rapidly from the start of the treatment, we completed CKR with a marginal dose of 21 Gy and a maximum of 38.9 Gy in three fractions over five days. At six weeks after CKR, the MRI showed complete resolution of not only the frontal bone lesion but also the occipital and orbital bone lesions that we did not directly target for irradiation. The maximum doses irradiated to the occipital and orbital bone lesions were 0.31 Gy and 0.34 Gy. Because of the marked shrinkage of the skull lesions, we suspected that the patient had a radiosensitive neoplastic disease. FDG-PET/CT revealed multiple lymph nodes and bone metastases. The patient underwent a scrotal biopsy, and the histologic diagnosis was DLBCL. The patient subsequently received chemotherapy for DLBCL. Ten months after CKR and six months after the start of chemotherapy for DLBCL, the patient died due to gastrointestinal bleeding. The skull lesions were well-controlled locally without adverse events due to CKR until the end of the life. Our present case suggests the importance of diagnosis and the effectiveness of low-dose CKR in the skull DLBCL.
颅骨弥漫性大B细胞淋巴瘤(DLBCL)较为罕见,目前尚无使用射波刀(CK)进行治疗的相关报道。在此,我们报告1例颅骨DLBCL患者接受低剂量CK放射治疗(CKR)后实现有效局部控制的病例。该患者为一名75岁男性,最初被诊断为肾盂癌多发颅骨转移(额骨、枕骨、右侧眶骨)。我们最初为额骨病变制定了CKR治疗计划,边缘剂量为35 Gy,每隔一天分5次给予,最大剂量为64.8 Gy。由于从治疗开始额骨病变迅速缩小,我们在5天内分3次完成了CKR,边缘剂量为21 Gy,最大剂量为38.9 Gy。CKR后6周,MRI显示不仅额骨病变完全消退,而且我们未直接靶向照射的枕骨和眶骨病变也完全消退。照射到枕骨和眶骨病变的最大剂量分别为0.31 Gy和0.34 Gy。由于颅骨病变明显缩小,我们怀疑该患者患有放射敏感性肿瘤疾病。氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)显示多处淋巴结和骨转移。患者接受了阴囊活检,组织学诊断为DLBCL。该患者随后接受了DLBCL化疗。CKR后10个月和DLBCL化疗开始后6个月,患者因胃肠道出血死亡。直至生命结束,颅骨病变通过CKR实现了良好的局部控制,且未出现不良事件。我们目前的病例表明了诊断的重要性以及低剂量CKR在颅骨DLBCL中的有效性。